drugset / Trial / NCT05512962
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.
Timeline
- Start
- 2022-08-31
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triamcinolone Acetonide | Other / unclassified | 2.4 mg | Other |
| Subject | Triamcinolone Acetonide | Other / unclassified | 4 mg | Other |